Real-World Studies
Immune Checkpoint Inhibitors Linked to Cystitis and Ureteritis in FAERS Analysis
Yuanyuan Zhang and Jiajin YangFrontiers in pharmacology

A dual-approach study combining a pooled analysis of published cases with a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) evaluated the clinical characteristics and pharmacovigilance signals of immune checkpoint inhibitor (ICI)-associated cystitis and ureteritis. In 28 published reports comprising 45 unique patients (median age 56 years; lung cancer was the most common underlying malignancy), common clinical presentations included urinary frequency, dysuria, hematuria, leukocyturia, and inflammatory abnormalities on imaging or cystoscopy. Upper urinary tract involvement was identified in 13 of 33 patients with available CT data, median time-to-onset was 62 days among 24 evaluable cases, patients showed corticosteroid responsiveness, and recurrence occurred in 5 of 9 patients who underwent drug rechallenge.
The pharmacovigilance evaluation analyzed 20,257,224 deduplicated FAERS CASEIDs spanning 2004Q1 to 2026Q1 using reporting odds ratios (RORs), proportional reporting ratios, chi-square statistics, and information components. A broad definition including IMMUNE-MEDIATED CYSTITIS, CYSTITIS NONINFECTIVE, URETERITIS, and CYSTITIS identified 397 ICI-associated cases with a weak disproportionality signal (ROR, 1.12; 95% CI, 1.02-1.24). In contrast, a high-specificity definition excluding the nonspecific Preferred Term CYSTITIS identified 151 cases and yielded a substantially stronger signal (ROR, 9.04; 95% CI, 7.63-10.70), which remained positive across sensitivity analyses and was observed at the class level. The authors conclude that ICI-associated cystitis and ureteritis represent an uncommon urothelial inflammatory immune-related adverse event spectrum, highlighting that phenotype-aware case definitions are critical to avoid signal dilution caused by nonspecific coding.
Key Takeaways
- In a FAERS disproportionality analysis of 20,257,224 deduplicated records, immune checkpoint inhibitor exposure yielded a marked signal under a high-specificity definition of cystitis and ureteritis (ROR, 9.04; 95% CI, 7.63-10.70), compared to a weak signal when using a broad definition that included nonspecific cystitis coding (ROR, 1.12; 95% CI, 1.02-1.24).
- In pooled published clinical cases, patients exhibited a median time-to-onset of 62 days, upper urinary tract involvement in 13 of 33 cases evaluated by CT, responsiveness to corticosteroids, and symptom recurrence in 5 of 9 patients who underwent rechallenge.
Read the original sourceFrontiers in pharmacology
